Dual GLP-1/GCG agonists such as mazdutide and survodutide are currently in phase 3 clinical trials as obesity treatments, with pemvidutide having recently completed phase 2 trials
& Watts, G
In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8-3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs, concluded the investigators
It may seem like the meds popped up out of nowhere, but the reality is they justtransferred
Instead, its helping mothers align their health and fitness goals after a monumental life event, and feel like themselves again, whether its about the number on the scale or lowering visceral fat, which helps reduce diseases like cardiovascular disease and type 2 diabetes